The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
Open accessAbstract
Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined. Methods: Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration. Results: The median (interquartile range) baseline Lp(a) concentration was 37 (13–165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01–1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%–46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r =0.37; 95% CI, 0.36–0.39; P <0.001). Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.67–0.88) in patients with a baseline Lp(a) >median, and by 7% (hazard ratio, 0.93; 95% CI, 0.80–1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively. Conclusions: Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, greater MACE reductions were seen among patients whose highly elevated Lp(a) levels were reduced by evolocumab [193].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [193]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This finding has also been supported by randomised control trials which shown that PCSK9 inhibition with evolocumab provides modest (16%) reduction in Lp(a) levels in patients with high Lp(a) levels43.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The net effect is a muted class response, with Lp(a) typically lowering around 20 to 30%, well below the reductions seen with LDL C and ApoB [25].”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although recent studies with PCSK9 inhibitors were not designed to target patients with high Lp(a) concentrations, they nevertheless revealed that patients with higher baseline Lp(a) concentration experienced greater absolute reductions in Lp(a) and tended to derive greater clinical benefit from PCSK9 inhibition [27,28].”
From Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM (2020) · cites this paper as [27]
The cited source says what the claim attributes to it.
In the citing paper
“evolocumab in the FOURIER trial reduced Lp(a) by a median of 26.9% at 48 weeks[2,25], and alirocumab in ODYSSEY OUTCOMES showed a median relative reduction of −23% by 4 months[3,26].”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [25]
In the citing paper
“In contrast, Mendelian randomization studies have consistently demonstrated that lifelong exposure to higher Lp(a) levels is strongly and causally associated with an increased risk of ASCVD [74,75].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationLipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationBurgess, S., Ference, B. A., Staley, J. R., Freitag, D. F., Mason, A. M., Nielsen, S. F., Willeit, P., Young, R., Surendran, P., Karthikeyan, S., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1470 · Cited by 689
Self-citationTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H. E., Blom, D. J., Eriksson, M., Dent, R. E., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 359
Self-citation
Cited by
Sorted by citations
Items 801–900 of 982
Study on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein
关, 桢. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133488
Wang, X., Tie, R., Cao, R., Yang, X., Xiao, W., Li, S., & Ye, P. (2023) · Cardiology Discovery · doi:10.1097/cd9.0000000000000088
Lipoprotein(a) in Cardiovascular Risk Assessment
Boffa, M. B., Koschinsky, M. L., & Marcovina, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00005-4
Cho, L., & Nissen, S. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00026-1
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
Marston, N., & Sabatine, M. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00020-0
Self-citationToth, P. P., Rizzo, M., & Banach, M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_27
Lavoie, M.-A., & Lanthier, L. (2023) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v18i1.662
The New Fat Kid on the Block: Lipoprotein (a)
Hussein, M. T. E., & Lewis, S. (2023) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2023.104731
Lipoproteína (a) y oligonucleótidos antisentido
Romero, J. A. C., Gomez, K. G. C., Ortigoza, M. P. M., & Saavedra-López, H. F. (2023) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.10.3.808
Lipoprotein (a) in Cardiovascular Risk Assessment and Management in Diabetes Mellitus
Francis, G. A. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.1315
“18,19 Novel agents that can lower Lp(a) very effectively, including antisense oligonucleotides and those that silence RNA against apo(a), are currently being tested in robust cardiovascular outcome trials to determine the additional benefit of lowering Lp(a) on a background of effective…”
BackgroundGómez-López, E. A., Molina, D. I., & Castillo, J. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000214
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and residual risk
García-Peña, Á. A., Zárate-Correa, L. C., & Monsalve, C. (2023) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m23000212
Kardiovaskulärer Risikofaktor Dyslipidämie
Lebherz, C., & Lehrke, M. (2023) · Springer Reference Medizin · doi:10.1007/978-3-662-62932-1_9
The influence of lipoproteina(a) on cardio-vascular diseases
Maj-Dziedzic, M., Brzozowska, A., Sikora, M., Zarzycka, M., Plewniok, I., Dubiel, J., Maj, A., Śmietana, G., Warno, M., & Kozik, W. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.54.013
Panorama general del riesgo cardiovascular residual
Aristizábal-Colorado, D., Quintero-Zea, K., & Sierra-Castillo, S. (2024) · Interdisciplinary Journal of Epidemiology and Public Health · doi:10.18041/2665-427x/ijeph.1.10357
Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities
Karp, A., Jacobs, M. M., Barris, B., Labkowsky, A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000667
“28,29”
Espoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
Xu, L., Wang, L., Wang, Y., Wang, Y., Jiang, Y., Du, P., Cheng, J., Zhang, C., Wang, R., Jiao, T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4008037/v1
Shah, N. P., Mulder, H. S., Lydon, B., Chiswell, K., Hu, X., Lampron, Z. M., Cohen, L., Patel, M. R., Taubes, S., Song, W., et al. (2024) · medRxiv · doi:10.1101/2024.03.07.24303948
“Finally, in secondary prevention populations, higher Lp(a) levels predict subsequent cardiovascular events and may warrant aggressive combination lipid lowering therapy 17 .”
BackgroundZhu, L., Zheng, J., Gao, B., Jin, X., He, Y., Zhou, L., & Huang, J. (2022) · Figshare · doi:10.6084/m9.figshare.19606714
Hima, H. N., & Ahmad, F. (2023) · International Conference on Industrial Engineering and Operations Management (IEOM) · doi:10.46254/ba06.20230158
IMPLICAÇÕES INFLAMATÓRIAS E CARDIOMETABÓLICAS NA OBESIDADE: PERSPECTIVAS E ATUALIDADES
Rocha, D. D. L., Silva, D. M. C. E., Pereira-Freire, J. A., & Morais, J. B. S. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240308827
Tada, H., Sakata, K., Usui, S., & Takamura, M. (2024) · Journal of Coronary Artery Disease · doi:10.7793/jcad.30.23-00023
Reiner, Ž., Miličić, D., Rogić, D., Manola, Š., Ružić, A., Canecki-Vražić, S., Kristić, I., Zulle, B.-L., Đerek, L., Šerić, V., et al. (2024) · Liječnički vjesnik · doi:10.26800/lv-146-1-2-7
Liang, D., Liang, D., Liu, J., Zheng, Y., Huang, D., Li, Z., Huang, X., & Chen, J. (2024) · Technology and Health Care · doi:10.3233/thc-240005
“…revealed the vital function of Fib and/or Lp(a) in promoting cardio-vascular disorder development [21,22,23,24,25] and CVEs [26,27,28,29,30,31] The ‘PROCAM’ study showed that, compared with healthy men with low low-density lipoprotein (LDL) and Fib levels, patients with high LDL and Fib…”
BackgroundZahid, A., Batool, A., Khan, M. A., Ahmad, A., Ullah, A., & Wajid, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4684994/v1
Aggarwal, A., & Jain, A. (2021) · Journal of internal medicine of India. · doi:10.4103/upjimi.upjimi_17_22
Zahid, A., Batool, A., Khan, M. A., Ahmad, A., Ullah, A., & Wajid, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4684994/v2
Telis, N., Dai, H., Waring, A. A., Kann, D., Wyman, D., White, S. J., Khuder, B., Tanudjaja, F., Bolze, A., Levy, M. E., et al. (2024) · medRxiv · doi:10.1101/2024.11.01.24316526
Siegler, J. E., Goicoechea, E. B., Yaghi, S. R., Morsi, R. Z., Arevalo, A., Smith, M. M., Kothari, S. A., Desai, H., Sehgal, N., Rana, R., et al. (2024) · medRxiv · doi:10.1101/2024.10.31.24316532
“These agents are known to lower lipoprotein(a) levels, 19 and may have local antiplatelet and anti-inflammatory effects at sites of plaque formation.”
BackgroundLipoprotein (a) Screening, and What's Next?
Pasławska, A., Radom, A., & Tomasik, P. (2024) · Journal of Cardiovascular Emergencies · doi:10.2478/jce-2024-0022
Maladkar, Y. T., & Kothiwale, V. A. (2024) · Journal of the Scientific Society · doi:10.4103/jss.jss_183_24
Genetics of Lp(a) and association with cardiovascular risk
Flores, C. F. Y., & Cabrera, A. T. M. (2025) · Bionatura journal : · doi:10.70099/bj/2025.02.01.4
Sapina, A. I., Varlamova, Y. Y., Papyrina, M. G., Bezymyannyy, A. S., Kordzaya, E. L., & Vasilyeva, E. Y. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6177
Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos
Moyá-Amengual, A., & Serrano-Cumplido, A. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102451
Shehab, H. F., Rajan, R., Al‐Jarallah, M., Dashti, R., Al-Sarraf, A. J., Alsaber, A., Tse, G., AlObaid, L., & Lansberg, P. J. (2025) · Annals of Clinical Cardiology · doi:10.4103/accj.accj_28_24
Lipoproteina(a): fattore di rischio cardiovascolare tra clinica e laboratorio
Bonetti, G., & Carta, M. (2025) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.25.00279-8
Angoulvant, D. (2025) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2025.03.013
Chen, J., Ling, Y., Wang, R., Shu, S., Liu, J., Yan, M., Chang-kong, Y., & Liu, S. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04737-1
“Recent advances in statistical prognostic modeling offer exciting opportunities to improve disease prediction by combining multimodal data [18– 20].”
Unveiling Lipoprotein(a): A New Frontier in Heart Health
Tabowei, G., Parepalli, D., Sanders, T., Ogedegbe, O. J., Sukhera, A. B., Alugba, G., Dadzie, S., Modi, B., Mejulu, E. O., Reyes, L. G., et al. (2025) · Indian Journal of Clinical Cardiology · doi:10.1177/26324636251341038
Association between elevated Lp(a) and CAV in heart transplant recipientsPreprint
Cao, L., Huang, S., Amancherla, K. V., ZALAWADIYA, S. K., Siddiqi, H. K., Schlendorf, K. H., Lindenfeld, J. M., & Song, W. (2025) · medRxiv · doi:10.1101/2025.05.26.25328315
“…do not lower Lp(a) sufficiently to reduce adverse cardiovascular events in the general population, and some work has found that statins may minimally increase Lp(a) levels 9 . tly s Recent work has suggested that PCSK9 inhibitors lower Lp(a) and potentially may reduce cardiovascular events 21,22 .”
What do recent observations reveal about the ‘blind date’ with Lp(a)-reducing drugs?
Kronenberg, F. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf324
Phenomapping of subgroups in high-Lp(a) patients: a data-driven cluster analysis in RED-CARPET study
Zhang, S., Lin, X., Zhan, R., Zhou, H., Lai, Y., Huang, M., Li, B., Liao, X., & Zhuang, X. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02669-6
“In contrast, a new class of LDL-c lowering drugs, PCSK9 inhibitors, such as Evolocumab [10] and Alirocumab [11], have been confirmed to be associated with a reduction in Lp(a) levels and a subsequent decrease in clinical events.”
Zhong, L., Lin, R., Cao, B., Zhong, W., Tu, M., & Wei, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1591108
“…universally recognized absolute risk threshold exists, approximately 20% to 25% of the global population has Lp(a) levels of 50 mg/dL or higher (24), conferring an elevated cardiovascular risk despite optimizing traditional risk factors (25), according to the European Atherosclerosis Society (EAS).”
Gao, Z., Arai, M., Ma, H., Chen, J., & Wu, P. (2025) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytaf309
Jang, M., Park, S., Ann, S. H., Kim, Y., Jeon, Y., Lim, S., Kwon, W. J., Choi, S. H., Han, S., & Park, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-04964-8
“These findings indicate that appropriate strategies for the primary prevention of CAD are necessary in patients with DM and elevated Lp(a) levels.”
Nicholls, S. J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001002 · Cited by 2
Bilder, G. E., & Brown-O’Hara, P. (2025) · Springer eBooks · doi:10.1007/978-3-031-84831-5_4
Korneva, V. A., & Kuznetsova, Т. Y. (2025) · Новые Санкт-Петербургские врачебные ведомости. · doi:10.24884/1609-2201-2025-104-1-32-43
Heneha, M. B., Marushko, Y. Y., & Mankovskyi, G. B. (2025) · Ukrainian journal of cardiovascular surgery · doi:10.63181/ujcvs.2025.33(3).25-30
Suta, S., Pinsawas, B., Surawit, A., Ophakas, S., Wang, Y., Du, Y. Y., Shen, X., Pasookhush, P., Mongkolsucharitkul, P., Soonkum, T., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-7577991/v1
Kommentar zu „Autoimmun-Erkrankung: LDL-Cholesterin-Senkung reduziert kardiovaskuläres Risiko“
Espinola-Klein, C. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2646-5914
Protocolo de prevención primaria y secundaria de la cardiopatía isquémica
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Iglesias-Álvarez, D., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.008
Association between elevated lipoprotein(a) levels and cardiovascular risk
Abushmaies, A. K., & Sufyan, M. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253757
Sbrana, F., Pino, B. D., Corciulo, C., Bigazzi, F., Casula, M., Catapano, A. L., Medde, P., Sampietro, T., Zenti, M. G., & Collaborators, G. S. (2025) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.70096
“…the additional cardiovascular risk reduction in patients with high Lp(a) concentrations, despite a modest Lp(a)- lowering, as revealed by FOURIER [17] and ODYSSEY trials [18]; (2) LA should be targeted at least in patients with very high Lp(a) concentrations (100 mg/dL to > 250 nmol/L) and…”
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
“[82 ].”
Kumar, P., Prajapathi, S., Singh, A., Pradhan, A. K., Shukla, A., Bhandari, M., Sharma, A., Vishwakarma, P., Chaudhary, G., Chandra, S., et al. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200558
Kar, S. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm41551 · Cited by 2
“%) along with LDL in the FOURIER trial [ 29].”
Lp(a) and cardiovascular risk: insights from a young multiethnic cohort in Dubai
Musumeci, G., & Quadri, G. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134085
Prognostic value of lipoprotein(a) in a primary prevention ambulatory cohort
Golan, N., Freund, O., Itach, T., & Arbel, Y. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02826-x
Cardiovascular Risk Factor Dyslipidemia
Lebherz, C., & Lehrke, M. (2025) · Springer eBooks · doi:10.1007/978-3-662-69938-6_9
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.25415009
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599987
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599972
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599978
Liu, H.-H., Yuanlin, G., Zhu, C.-G., Wu, N.-Q., Gao, Y., Xu, R.-X., Dong, Q., Qian, J., Dou, K.-F., & Li, J.-J. (2022) · Figshare · doi:10.6084/m9.figshare.19906009
Zhao, L. Y., Sun, L., Zhang, Z., Yang, K., Li, Z., Wang, M., Zeng, Y., Zhou, X., & Yang, W. (2023) · Figshare · doi:10.6084/m9.figshare.24078414
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599969
Liu, M.-M., Peng, J., Guo, Y.-L., Zhu, C.-G., Wu, N.-Q., Xu, R.-X., Dong, Q., & Li, J.-J. (2021) · Figshare · doi:10.6084/m9.figshare.17141260
Zhu, L., Fang, Y., Gao, B., Jin, X., Zheng, J., He, Y., & Huang, J. (2022) · Figshare · doi:10.6084/m9.figshare.21522073
Yu, M., Zhao, X., Chen, Y.-Y., Tao, X.-W., Ge, J.-B., Jin, H., & Zeng, M.-S. (2023) · Figshare · doi:10.6084/m9.figshare.23084080
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.25414832
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600008
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599984
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599996
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599975
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600005
Yoon, D., Choi, B., Kim, J.-E., Kim, E.-Y., Chung, S.-H., Min, H.-J., Sung, Y., Chang, E.-J., & Song, J.-K. (2024) · Figshare · doi:10.6084/m9.figshare.26693500
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600011
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600026
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600035
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599990
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600029
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600002
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599999
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599981
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600032
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600023
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26599993
Li, N., Zhou, J., Chen, R., Zhao, X., Li, J., Zhou, P., Liu, C., Chen, Y., Wang, Y., Song, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600014
Coronary Artery Calcification and Lipid-Lowering Treatment
Kim, J. S. (2025) · Journal of Cardiovascular Intervention · doi:10.54912/jci.2025.0026
Guo, J., Huang, F., Lu, P., & Lu, M.-J. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/4885476
“In recent years, multiple genomic studies have identi fi ed susceptibility genes such as PCSK9 and LPA associated with CHD risk, providing important clues to the molecular basis of the disease [6, 7].”
Zhang, Z., Zhao, L. Y., Wang, Z., Zhou, X., Li, X. X., Yang, W., & Xu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70491
Overview of the Study of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease
王, 然. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161286
Wong, N. D., Kianoush, S., & Barseghian, A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag060
Lipoprotein(a): Moving Beyond Recognition to Intervention
Khanna, S., Nerlekar, N., & Bhat, A. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.009
Mehta, K. A., Tated, R. C. P., Gupta, U., Singh, A. M., Elias, S., Sharma, S., Feroze, R. A., & Arora, S. (2026) · Research Square · doi:10.21203/rs.3.rs-8606687/v1
Lipoprotein(a) in familial hypercholesterolemia
Jaafar, A. K., Bourane, S., Lambert, G. C., & Chemello, K. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001032
Metadata
- Authors
- O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., Ezhov, M. V., Jukema, J. W., Jensen, H. K., Tokgözoğlu, S. L., Mach, F., Huber, K., Sever, P. S., Keech, A. C., Pedersen, T. R., & Sabatine, M. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Polyclinic for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Germany (I.G.-B.).
- Amgen, Thousand Oaks, CA (A.L.P., S.M.W.).
- Amgen (United States) (US)
- Charles University (CZ)
- National Cardiology Research Center, Moscow, Russia (M.V.E.).
- Leiden University Medical Center (NL)
- Aarhus University (DK)
- Cardiovascular Division, Hacettepe University, Ankara, Turkey (S.L.T.).
- University of Geneva (CH)
- Sigmund Freud Privatuniversität Wien (AT)
- Imperial College London (GB)
- The University of Sydney (AU)
- Oslo University Hospital (NO)
- ORCID
- Venue
- Circulation
- Published
- 2019-03-19
- Volume
- 139
- Issue
- 12
- Pages
- 1483-1492
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2940327706
- Cited by
- 984
- References
- 33
- Citations by year
- 2026: 133 · 2025: 153 · 2024: 157 · 2023: 134 · 2022: 120 · 2021: 100 · 2020: 122 · 2019: 64
- FWCI
- 97.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Abbott Laboratories
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Brigham and Women's Hospital
- Gilead Sciences
- Alnylam Pharmaceuticals
- Univerzita Karlova v Praze
- Aarhus Universitet
- Aarhus Universitetshospital
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Amarin Corporation
- Medicines Company
- Mylan
- MyoKardia
- Imperial College London
- Universiteit Leiden
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Leids Universitair Medisch Centrum
- Universitetet i Oslo
- Hacettepe Üniversitesi
- Université de Genève
- Universität zu Köln
- Novo Nordisk Fonden (NNF18OC0031258)
- Servier
- Esperion Therapeutics
- Medical Research Council
- National Health and Medical Research Council
- Sydney Medical School
- Janssen Research and Development
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- lipoprotein(a), PCSK9 inhibitors, evolocumab, cardiovascular risk, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, urgent revascularization, LDL cholesterol, prognostic factors, FOURIER trial, LDL cholesterol lowering
- MeSH terms
- Proprotein Convertase 9, Adult, Aged, Aged, 80 and over, Anticholesteremic Agents, Double-Blind Method, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Placebo Effect, Proportional Hazards Models, Treatment Outcome, Lipoprotein(a), Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
